geneonline.com
Palisade Bio to Present Data on PDE4 Inhibitor PALI-2108 for Fibrostenotic Crohn's Disease ...
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research proves effective and safe.
Patients with fibrostenotic Crohn’s disease, gastroenterologists and IBD clinicians, and researchers interested in anti-fibrotic or PDE4-targeted therapies.
What To Know
Palisade Bio will present data on PALI-2108, a PDE4 inhibitor being developed to target fibrotic (fibrostenotic) complications of Crohn’s disease.
The article summarizes that the presentation will cover the drug’s mechanism and clinical objectives and frames the therapy as an investigational candidate intended to address intestinal strictures by modulating inflammatory and fibrotic pathways.
This appears to be a conference presentation (New York Academy of Sciences symposium) rather than a completed late-stage trial or approval announcement. The company will discuss scientific rationale and early-stage clinical aims rather than published phase 3 results or regulatory decisions.
There is no detailed efficacy or safety data in the piece, and no immediate change to clinical care is described. For patients, this is an update that a novel antifibrotic approach is under investigation for fibrostenotic Crohn’s disease.
If you want the original source, the article is a short press-style notice on GeneOnline summarizing the planned conference presentation.
This is a conference presentation notice about an investigational PDE4 inhibitor; the article does not provide trial results, sample sizes, or timelines. Early-stage research and company presentations often focus on rationale and objectives—they do not imply proven benefit or regulatory approval.
